Tuberculosis Screening and Reactivation among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists

Inflammatory Bowel Diseases

Volumn 23, Issue 2, 2017, Pages 254-260

  Hou, Jason K ^a,b   Kramer, Jennifer R ^a,b   Richardson, Peter ^a,b   Sansgiry, Shubhada ^a,b,c   El Serag, Hashem B ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c South Central Mental Illness Research Education and Clinical Center   (United States)

Author keywords

complications of therapy; Crohn's disease; reactivation; tuberculosis; tumor necrosis factor antagonists; ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; ISONIAZID; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; POSTPRIMARY TUBERCULOSIS; PRESCRIPTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TUBERCULOSIS CONTROL; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COHORT ANALYSIS; EVALUATION STUDY; LATENT TUBERCULOSIS; MASS SCREENING; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TUBERCULIN TEST; UNITED STATES;

ADALIMUMAB; ADULT; AGED; CERTOLIZUMAB PEGOL; COHORT STUDIES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; ODDS RATIO; RECURRENCE; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 85006365356     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000001003     Document Type: Article

References (22)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
2. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-894.
3. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48:2122-2127.
4. Gómez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57:756-761.
5. Kim ES, Song GA, Cho KB, et al. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol. 2015;21: 3308-3316.
6. Byun JM, Lee CK, Rhee SY, et al. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factora blockers. J Korean Med Sci. 2015;30:173-179.
7. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385-1397.
8. Available at: http://www.gastro.org/practice-management/quality/ 2015-AGA-Measures-IBD.pdf. Accessed March 1, 2016.
9. Carpio D, Jauregui-Amezaga A, de Francisco R, et al. Tuberculosis in antitumour necrosis factor-treated inflammatory bowel disease patients after the Implementation of preventive measures: compliance with recommendations and safety of retreatment. J Crohns Colitis. 2016;10:1186-1193.
10. van der Have M, Belderbos TD, Fidder HH, et al. Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014;46:881-886.
11. Peyrin-Biroulet L, Oussalah A, Boucekkine T, et al. TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine. Gastroentérol Clin Biol. 2009;33:23-30.
12. Feuerstein JD, Castillo NE, Siddique SS, et al. Poor documentation of inflammatory bowel disease quality measures in academic, community, and private practice. Clin Gastroenterol Hepatol. 2016;14: 421-428.e2.
13. Vaughn BP, Doherty GA, Gautam S, et al. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflamm Bowel Dis. 2012;18:1057-1063.
14. Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5: 1070-1075.
15. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-313.
16. Hou JK, Tan M, Stidham RW, et al. Accuracy of diagnostic codes for identifying patients with ulcerative colitis and Crohn's disease in the veterans affairs health care system. Dig Dis Sci. 2014;59:2406-2410.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45:613-619.
18. Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161:419-428.
19. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10:1127-1132.
20. Dorn SD. Quality measurement in gastroenterology: confessions of a realist. Clin Gastroenterol Hepatol. 2016;14:648-650.
21. Thirumurthi S, Chowdhury R, Richardson P, et al. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci. 2010;55:2592-2598.
22. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis. 2007;13:451-461.